SCHEMBL24087930

SCHEMBL24087930

N#Cc1c(SCc2cccc(Cc3nc(=O)o[nH]3)c2)[nH]c(=O)c(C#N)c1-c1cccs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACMSD Q8TDX5 8/20 0.49
▸ KMT2A Q03164 6/20 0.47
▸ MAPT P10636 6/20 0.47
▸ NPSR1 Q6W5P4 5/20 0.47
▸ MEN1 O00255 5/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ HPGD P15428 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ CYP2C19 P33261 2/20 0.44
▸ PRNP P04156 3/20 0.43
▸ RXFP1 Q9HBX9 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ SAE1 Q9UBE0 1/20 0.43
▸ UBA2 Q9UBT2 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24087933 0.88 NPSR1 (0.44) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL24087958 0.87 ACMSD (0.46) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL26847391 0.84 ACMSD (0.47) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL24087931 0.84 ACMSD (0.47) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL26847386 0.80 ACMSD (0.46) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL23850227 0.79 ACMSD (0.68) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL24087881 0.76 KDM4E (0.45) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL26847375 0.76 KDM4E (0.44) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL24087894 0.76 KDM4E (0.48) ACMSDKMT2AMAPTNPSR1MEN1
SCHEMBL23852405 0.75 ACMSD (0.52) ACMSDKMT2AMAPTNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S.R.L. (IT) 2023-11-30 — — US disclosed
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S R L (IT) 2021-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 ACMSD 1/4885KMT2A 1353/4885MAPT 1263/4885
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 ACMSD 1/4885KMT2A 1353/4885MAPT 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback